Silexion Therapeutics Ltd. (SLXNW) Earnings History
Annual and quarterly earnings data from 2020 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export SLXNW earnings history in CSV or JSON format
Free sign-in required to download data
Silexion Therapeutics Ltd. (SLXNW) Earnings Overview
As of February 28, 2026, Silexion Therapeutics Ltd. (SLXNW) reported trailing twelve-month net income of -$9M, reflecting +64.4% year-over-year growth. The company earned $-8.16 per diluted share over the past four quarters.
Looking at the long-term picture, SLXNW's historical earnings data spans multiple years. The company achieved its highest annual net income of $584,025 in fiscal 2022.
Silexion Therapeutics Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including ALNY ($314M net income, 0.1% margin), IONS (-$381M net income, -0.4% margin), ARWR ($202M net income, -0.0% margin), SLXNW has comparable earnings metrics. Compare SLXNW vs ALNY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$16M | -232.7% | -$13M | $25.49 | - | - |
| 2023 | -$5M | -946.2% | -$5M | $0.39 | - | - |
| 2022 | $584,025 | +177.3% | -$1M | $0.35 | - | - |
| 2021 | $-755,218 | -285.6% | $-943,933 | $-0.46 | - | - |
| 2020 | $-195,860 | - | $-195,860 | $-0.12 | - | - |
See SLXNW's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLXNW Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SLXNW vs AGIO
See how SLXNW stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SLXNW growing earnings?
SLXNW EPS is $-8.16, with earnings growth accelerating to +64.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-9M.
What are SLXNW's profit margins?
Silexion Therapeutics Ltd. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SLXNW's earnings?
SLXNW earnings data spans 2020-2024. The accelerating earnings trend is +64.4% YoY. Historical data enables comparison across business cycles.